PW
ESPR

Pandora Wealth’s Esperion Therapeutics ESPR Stock Holding History

Pandora Wealth’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$27.8K Hold
7,500
– – 0.02% 164
2025
Q3 		$19.9K Hold
7,500
– – 0.01% 168
2025
Q2 		$7.38K Hold
7,500
– – ﹤0.01% 203
2025
Q1 		$10.8K Buy
+7,500
New +$13.8K 0.01% 188

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Pandora Wealth's ESPR Position: Q4 2025 in Review

Pandora Wealth held its Esperion Therapeutics (ESPR) position steady in Q4 2025 at 7,500 shares worth $27.8K. The position accounts for 0.02% of the portfolio, ranked #164.

Pandora Wealth first reported a position in ESPR in Q1 2025 and has held it in 4 quarters since. 200 funds tracked by Wall St. Rank hold ESPR as of Q4 2025.

  • Pandora Wealth held 7,500 shares of Esperion Therapeutics worth $27.8K as of Q4 2025.
  • Pandora Wealth left its Esperion Therapeutics share count unchanged in Q4 2025.
  • Esperion Therapeutics made up 0.02% of Pandora Wealth's portfolio in Q4 2025, its #164 holding.
  • Pandora Wealth first reported a position in Esperion Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • 200 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2025.

Based on Pandora Wealth's 13F filing for Q4 2025, filed 4 Feb 2026.